vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and Varex Imaging Corp (VREX). Click either name above to swap in a different company.
Varex Imaging Corp is the larger business by last-quarter revenue ($209.6M vs $185.2M, roughly 1.1× AMICUS THERAPEUTICS, INC.). Varex Imaging Corp runs the higher net margin — 1.1% vs 0.9%, a 0.2% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 4.9%). AMICUS THERAPEUTICS, INC. produced more free cash flow last quarter ($16.0M vs $-26.8M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 0.8%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
Varex Imaging Corp is a global supplier of advanced imaging components and solutions, including X-ray tubes, digital flat panel detectors, and image processing software. Its products serve medical imaging, radiation oncology, and industrial non-destructive testing segments, with customers across key global markets.
FOLD vs VREX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $209.6M |
| Net Profit | $1.7M | $2.3M |
| Gross Margin | 85.7% | 33.3% |
| Operating Margin | 8.6% | 7.3% |
| Net Margin | 0.9% | 1.1% |
| Revenue YoY | 23.7% | 4.9% |
| Net Profit YoY | -88.5% | 866.7% |
| EPS (diluted) | $0.00 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $209.6M | ||
| Q4 25 | $185.2M | $228.9M | ||
| Q3 25 | $169.1M | $203.0M | ||
| Q2 25 | $154.7M | $212.9M | ||
| Q1 25 | $125.2M | $199.8M | ||
| Q4 24 | $149.7M | — | ||
| Q3 24 | $141.5M | $205.7M | ||
| Q2 24 | $126.7M | $209.1M |
| Q1 26 | — | $2.3M | ||
| Q4 25 | $1.7M | $12.2M | ||
| Q3 25 | $17.3M | $-89.1M | ||
| Q2 25 | $-24.4M | $6.9M | ||
| Q1 25 | $-21.7M | $-300.0K | ||
| Q4 24 | $14.7M | — | ||
| Q3 24 | $-6.7M | $-51.1M | ||
| Q2 24 | $-15.7M | $1.4M |
| Q1 26 | — | 33.3% | ||
| Q4 25 | 85.7% | 34.0% | ||
| Q3 25 | 88.5% | 33.3% | ||
| Q2 25 | 90.2% | 36.0% | ||
| Q1 25 | 90.7% | 34.3% | ||
| Q4 24 | 90.1% | — | ||
| Q3 24 | 90.6% | 32.6% | ||
| Q2 24 | 91.1% | 32.0% |
| Q1 26 | — | 7.3% | ||
| Q4 25 | 8.6% | 8.6% | ||
| Q3 25 | 20.3% | -39.8% | ||
| Q2 25 | -6.1% | 10.4% | ||
| Q1 25 | -6.3% | 5.6% | ||
| Q4 24 | 10.7% | — | ||
| Q3 24 | 15.3% | 5.3% | ||
| Q2 24 | 11.8% | 4.4% |
| Q1 26 | — | 1.1% | ||
| Q4 25 | 0.9% | 5.3% | ||
| Q3 25 | 10.2% | -43.9% | ||
| Q2 25 | -15.8% | 3.2% | ||
| Q1 25 | -17.3% | -0.2% | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | -4.8% | -24.8% | ||
| Q2 24 | -12.4% | 0.7% |
| Q1 26 | — | $0.05 | ||
| Q4 25 | $0.00 | $0.29 | ||
| Q3 25 | $0.06 | $-2.15 | ||
| Q2 25 | $-0.08 | $0.17 | ||
| Q1 25 | $-0.07 | $-0.01 | ||
| Q4 24 | $0.05 | — | ||
| Q3 24 | $-0.02 | $-1.25 | ||
| Q2 24 | $-0.05 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $125.6M |
| Total DebtLower is stronger | $392.7M | $367.6M |
| Stockholders' EquityBook value | $274.2M | $476.9M |
| Total Assets | $949.9M | $1.1B |
| Debt / EquityLower = less leverage | 1.43× | 0.77× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $125.6M | ||
| Q4 25 | $293.5M | $155.1M | ||
| Q3 25 | $263.8M | $152.6M | ||
| Q2 25 | $231.0M | $223.0M | ||
| Q1 25 | $250.6M | $212.6M | ||
| Q4 24 | $249.9M | — | ||
| Q3 24 | $249.8M | $200.5M | ||
| Q2 24 | $260.1M | $190.0M |
| Q1 26 | — | $367.6M | ||
| Q4 25 | $392.7M | $367.5M | ||
| Q3 25 | $392.0M | $367.5M | ||
| Q2 25 | $391.3M | $567.2M | ||
| Q1 25 | $390.7M | $567.0M | ||
| Q4 24 | $390.1M | — | ||
| Q3 24 | $389.5M | $443.4M | ||
| Q2 24 | $388.9M | $443.1M |
| Q1 26 | — | $476.9M | ||
| Q4 25 | $274.2M | $472.6M | ||
| Q3 25 | $230.4M | $455.3M | ||
| Q2 25 | $204.3M | $549.7M | ||
| Q1 25 | $193.6M | $540.2M | ||
| Q4 24 | $194.0M | — | ||
| Q3 24 | $178.8M | $529.1M | ||
| Q2 24 | $132.5M | $581.2M |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $949.9M | $1.1B | ||
| Q3 25 | $868.8M | $1.1B | ||
| Q2 25 | $815.3M | $1.4B | ||
| Q1 25 | $789.8M | $1.3B | ||
| Q4 24 | $785.0M | — | ||
| Q3 24 | $786.6M | $1.2B | ||
| Q2 24 | $749.5M | $1.3B |
| Q1 26 | — | 0.77× | ||
| Q4 25 | 1.43× | 0.78× | ||
| Q3 25 | 1.70× | 0.81× | ||
| Q2 25 | 1.92× | 1.03× | ||
| Q1 25 | 2.02× | 1.05× | ||
| Q4 24 | 2.01× | — | ||
| Q3 24 | 2.18× | 0.84× | ||
| Q2 24 | 2.93× | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $-16.1M |
| Free Cash FlowOCF − Capex | $16.0M | $-26.8M |
| FCF MarginFCF / Revenue | 8.6% | -12.8% |
| Capex IntensityCapex / Revenue | 0.2% | 5.1% |
| Cash ConversionOCF / Net Profit | 9.62× | -7.00× |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | $-13.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-16.1M | ||
| Q4 25 | $16.3M | $7.9M | ||
| Q3 25 | $35.7M | $7.7M | ||
| Q2 25 | $-26.5M | $16.6M | ||
| Q1 25 | $7.8M | $9.5M | ||
| Q4 24 | $-3.9M | — | ||
| Q3 24 | $-23.0M | $25.9M | ||
| Q2 24 | $22.7M | $8.0M |
| Q1 26 | — | $-26.8M | ||
| Q4 25 | $16.0M | $2.3M | ||
| Q3 25 | $35.3M | $1.4M | ||
| Q2 25 | $-28.9M | $9.8M | ||
| Q1 25 | $7.5M | $5.3M | ||
| Q4 24 | $-4.2M | — | ||
| Q3 24 | $-23.3M | $19.9M | ||
| Q2 24 | $21.6M | $3.3M |
| Q1 26 | — | -12.8% | ||
| Q4 25 | 8.6% | 1.0% | ||
| Q3 25 | 20.9% | 0.7% | ||
| Q2 25 | -18.7% | 4.6% | ||
| Q1 25 | 6.0% | 2.7% | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | -16.5% | 9.7% | ||
| Q2 24 | 17.0% | 1.6% |
| Q1 26 | — | 5.1% | ||
| Q4 25 | 0.2% | 2.4% | ||
| Q3 25 | 0.2% | 3.1% | ||
| Q2 25 | 1.6% | 3.2% | ||
| Q1 25 | 0.2% | 2.1% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.3% | 2.9% | ||
| Q2 24 | 0.9% | 2.2% |
| Q1 26 | — | -7.00× | ||
| Q4 25 | 9.62× | 0.65× | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 5.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
VREX
| Medical Segment | $144.8M | 69% |
| Industrial Segment | $64.8M | 31% |
